niacinamide has been researched along with Cancer of Endometrium in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma." | 1.46 | Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. ( Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A, 2017) |
| "We exposed a panel of 12 endometrial cancer cell lines to a PI3K/mTOR inhibitor (voxtalisib, SAR245409) and/or a MEK inhibitor (pimasertib)." | 1.42 | Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. ( Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T, 2015) |
| "Sorafenib treatment correlated with a downregulation of both FLICE-Inhibitory Protein (FLIP) and myeloid cell leukaemia-1 (Mcl-1), caused by a proteasomal degradation of both proteins." | 1.36 | The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. ( Dolcet, X; Domingo, M; Eritja, N; Gonzalez-Tallada, FJ; Llobet, D; Matias-Guiu, X; Pallares, J; Santacana, M; Sorolla, A; Yeramian, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, NK | 1 |
| Huang, SL | 1 |
| Chang, TC | 1 |
| Chao, CC | 1 |
| Inaba, K | 1 |
| Oda, K | 1 |
| Ikeda, Y | 1 |
| Sone, K | 1 |
| Miyasaka, A | 1 |
| Kashiyama, T | 1 |
| Fukuda, T | 1 |
| Uehara, Y | 1 |
| Arimoto, T | 1 |
| Kuramoto, H | 1 |
| Wada-Hiraike, O | 1 |
| Kawana, K | 1 |
| Yano, T | 1 |
| Osuga, Y | 1 |
| Fujii, T | 1 |
| Mirantes, C | 1 |
| Dosil, MA | 1 |
| Eritja, N | 3 |
| Felip, I | 1 |
| Gatius, S | 2 |
| Santacana, M | 3 |
| Matias-Guiu, X | 3 |
| Dolcet, X | 3 |
| Chen, BJ | 1 |
| Rodríguez-Barrueco, R | 1 |
| Vidal, A | 1 |
| Martí, MD | 1 |
| Ponce, J | 1 |
| Bergadà, L | 1 |
| Yeramian, A | 2 |
| Encinas, M | 1 |
| Ribera, J | 1 |
| Reventós, J | 1 |
| Boyd, J | 1 |
| Villanueva, A | 1 |
| Llobet-Navàs, D | 1 |
| Llobet, D | 1 |
| Pallares, J | 1 |
| Sorolla, A | 1 |
| Domingo, M | 1 |
| Gonzalez-Tallada, FJ | 1 |
5 other studies available for niacinamide and Cancer of Endometrium
| Article | Year |
|---|---|
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; ets-Domain Protein Elk-1; | 2013 |
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synerg | 2015 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neo | 2016 |
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neopla | 2017 |
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Be | 2010 |